Acta Materia Medica, Journal Year: 2024, Volume and Issue: 3(2)
Published: Jan. 1, 2024
Cancer is the leading cause of morbidity and mortality worldwide an important barrier to lengthening life expectancy in every country. Natural products are receiving increased attention from researchers globally increasing numbers natural approved for clinical studies involving cancer recent years. To gain more insight into that have undergone trials treatment, a comprehensive search was conducted. The https://clinicaltrials.gov website searched relevant product information up December 2022. terms included different types cancers, such as colorectal, lung, breast, gynecologic, kidney, bladder, melanoma, pancreatic, hepatocellular, gastric haematologic. Then, PubMed Web Science were articles February 2024. Hence, we listed existing about used treatment cancers discussed preclinical some promising their targets, indications, underlying mechanisms action. Our intent provide basic readers who interested or majoring obtain deeper understanding progress actions
Language: Английский
Citations
19O-GlcNAcylation regulation of RIPK1-dependent apoptosis dictates sensitivity to sunitinib in renal cell carcinoma
Drug Resistance Updates, Journal Year: 2024, Volume and Issue: 77, P. 101150 - 101150
Published: Sept. 12, 2024
Language: Английский
Citations
5Polyphenols: Potential Applications in Cancer Therapy
Molecular Nutrition & Food Research, Journal Year: 2025, Volume and Issue: unknown
Published: March 27, 2025
Polyphenols (PFs) are compounds found in fruits and vegetables, known for their health-related benefits, mainly including antioxidant, antiinflammatory, anticancer properties. However, efficacy is limited by poor bioavailability due to issues like low solubility, rapid metabolism, extensive excretion. Thus, research has focused on improving delivery systems, such as, example, nanoparticles, hydrogels, cocrystals, or conjugation with carrier molecules, which may protect PFs from degradation, improve and/or facilitate targeted cancer cells. promising modulating cancer-related pathways cell proliferation death, metastatic invasion, though translation patients hindered complex mechanisms. This review analyzes factors that affect PF bioavailability, evidences of vivo effects animal models mechanisms, results clinical trials, strategies enhance bioavailability. The idea need directly interact the challenged. Future aims optimize combine standard treatments, explore epigenetic effects, modulation tumor microenvironment, interactions gut microbiota. Advances personalized medicine structural modifications stability absorption could further potential. Despite challenges, remain a avenue complementary oncotherapy solutions.
Language: Английский
Citations
0Nano-Engineered Epigallocatechin Gallate (EGCG) Delivery Systems: Overcoming Bioavailability Barriers to Unlock Clinical Potential in Cancer Therapy
AAPS PharmSciTech, Journal Year: 2025, Volume and Issue: 26(5)
Published: May 16, 2025
Language: Английский
Citations
0pH-Sensitive Nanoparticles of Epigallocatechin-3-Gallate in Enhanced Colorectal Cancer Therapy
Nanomedicine, Journal Year: 2024, Volume and Issue: 19(6), P. 459 - 481
Published: Jan. 15, 2024
Aim: Encapsulating epigallocatechin-3-gallate (EGCG) in pH-sensitive polymeric nanoparticles for targeted delivery of drugs could revolutionize colorectal cancer treatment. Materials & methods: Nanoparticles were synthesized to release at colon pH. Dynamic light scattering measured their average diameter and ζ-potential, while differential scanning calorimetry x-ray diffraction assessed EGCG encapsulation. Results: The showed stability bioavailability the gastrointestinal tract, efficiently encapsulating releasing over 93% pH 7.2. They enhanced cytotoxicity against HT-29 cells demonstrated antibacterial properties, increasing apoptosis cell cycle arrest. Conclusion: study underscores potential enhancing therapy, aiming minimize side effects improve therapeutic outcomes.
Language: Английский
Citations
3Natural products for enhancing the sensitivity or decreasing the adverse effects of anticancer drugs through regulating the redox balance
Chinese Medicine, Journal Year: 2024, Volume and Issue: 19(1)
Published: Aug. 20, 2024
Redox imbalance is reported to play a pivotal role in tumorigenesis, cancer development, and drug resistance. Severe oxidative damage general consequence of cell responses treatment may cause death or severe adverse effects. To maintain their longevity, cells can rescue redox balance enter state resistance anticancer drugs. Therefore, targeting signalling pathways has emerged as an attractive prospective strategy for enhancing the efficacy drugs decreasing Over past few decades, natural products (NPs) have become invaluable source developing new due high low toxicity. Increasing evidence demonstrated that many NPs exhibit remarkable antitumour effects, whether used alone adjuvants, are emerging effective approaches enhance sensitivity decrease effects conventional therapies by regulating balance. Among them several novel based on entered clinical trials. In this review, we summarize synergistic related mechanisms combination with We believe regulation will represent promising candidates provide prospects future.
Language: Английский
Citations
2Unraveling the Role of Long Non-Coding RNAs in Therapeutic Resistance in Acute Myeloid Leukemia: New Prospects & Challenges
Non-coding RNA Research, Journal Year: 2024, Volume and Issue: 9(4), P. 1203 - 1221
Published: May 20, 2024
Acute Myeloid Leukemia (AML) is a fatal hematological disease characterized by the unchecked proliferation of immature myeloid blasts in different tissues developed various mutations hematopoiesis. Despite intense chemotherapeutic regimens, patients often experience poor outcomes, and many relapses leading to substandard remission rates. In recent years, long non-coding RNAs (lncRNAs) have increasingly become important prognostic therapeutic hotspots, due their contributions dysregulating functional epigenetic, transcriptional, post-translational mechanisms alterations cell expressions, resulting increased chemoresistance reduced apoptosis leukemic cells. Through this review, I highlight discuss latest advances understanding major through which lncRNAs confer therapy resistance AML. addition, also provide perspective on current strategies target lncRNA expressions. A better knowledge critical role that play controlling treatment outcomes AML will help improve existing medications devise new ones.
Language: Английский
Citations
1Griffithazanone A, a sensitizer of EGFR-targeted drug in Goniothalamus yunnanensis for non-small cell lung cancer
Heliyon, Journal Year: 2024, Volume and Issue: 10(19), P. e38489 - e38489
Published: Sept. 26, 2024
Language: Английский
Citations
1Parkin deficiency aggravates inflammation-induced acute lung injury by promoting necroptosis in alveolar type II cells
Chinese Medical Journal - Pulmonary and Critical Care Medicine, Journal Year: 2024, Volume and Issue: 2(4), P. 265 - 278
Published: Dec. 1, 2024
Necroptosis is a form of programmed cell death resulting in tissue inflammation due to the release intracellular contents. Its role and regulatory mechanism context acute lung injury (ALI) are unclear. Parkin (Prkn), an E3 ubiquitin ligase, has recently been implicated regulation necroptosis. In this study, we aimed investigate process ALI. Lipopolysaccharides (LPS)-induced mouse ALI model was utilized, pathological changes tissues were characterized. To elucidate roles necroptosis context, mixed lineage kinase domain-like (Mlkl) knockout mice, Prkn conditional inhibitor employed. Additionally, alveolar type 2 (AT2) cell-specific deletion lineage-tracing mice introduced explore specific mechanisms AT2 cells. A dose-dependent increase expression following LPS administration observed, correlating with shift from epithelial apoptosis Notably, depletion MLKL significantly mitigated associated ALI, particularly inflammatory response. Conversely, exacerbated pathology, enhancing necroptosis, This led increased post-LPS fibrosis. However, treatment GSK872, inhibitor, substantially phenotype induced by deletion. Importantly, impaired proliferation differentiation cells into AT1 These findings underscore multifaceted progression injury, inflammation, fibrosis through Therefore, may hold potential as therapeutic target for managing
Language: Английский
Citations
1Effect of Erlotinib Combined with Radiotherapy on Proliferation and Apoptosis of Human Non-Small Cell Lung Cancer Cells and its Possible Mechanism Exploration
Indian Journal of Pharmaceutical Sciences, Journal Year: 2024, Volume and Issue: 86(1)
Published: Jan. 1, 2024
To explore the effects and possible mechanisms of erlotinib combined with radiotherapy on proliferation apoptosis human non-small cell lung cancer cells. Blank control group, group were set cells in blank bronchial epithelioid without any treatment cultured routinely. The ability three groups was detected by counting kit-8, Western blot used to assess protein expression, quantitative polymerase chain reaction measure messenger ribonucleic acid Transwell determine metastatic potential. quantity migrating rate growth higher than that group; metastasis activity number reduced group. invasion overall apoptotic proteins Fas, B-cell lymphoma 2-associated X Fas ligand 2 non- small 5' adenosine monophosphate-activated kinase peroxisome proliferator-activated receptor coactivator-1 alpha mitogen-activated those mechanism erlotinib’s capacity lower viability cells, block their proliferation, migration, ability, induce may be connected kinase/ signaling pathway.
Language: Английский
Citations
0